{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:07:50Z","timestamp":1792066070603,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clml.2021.07.028","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T17:18:37Z","timestamp":1627838317000},"page":"e41-e56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-2183","authenticated-orcid":false,"given":"Richard","family":"LeBlanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-5453","authenticated-orcid":false,"given":"Debra J.","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8872-1934","authenticated-orcid":false,"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.028_bib0001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.028_bib0002","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0003","series-title":"Canadian Cancer Statistics 2019","year":"2019"},{"key":"10.1016\/j.clml.2021.07.028_bib0004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.07.028_bib0005","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1182\/blood-2019-121786","article-title":"Population-level trends in early mortality and overall survival of patients with multiple myeloma. are we facing stagnation?","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood-2019-121672","article-title":"Undertreatment of older patients with newly-diagnosed multiple myeloma: real world evidence from a canadian registry cohort","volume":"134","author":"Mian","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.028_bib0008","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0010","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.028_bib0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.07.028_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","article-title":"Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group","volume":"8","author":"Moulopoulos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.07.028_bib0013","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.14827","article-title":"Guidelines for the use of imaging in the management of patients with myeloma","volume":"178","author":"Chantry","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0014","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bone.2018.09.013","article-title":"FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients","volume":"121","author":"Atrash","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.clml.2021.07.028_bib0016","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0017","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.07.028_bib0018","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: american society of clinical oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2021.07.028_bib0020","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the medical research council myeloma IX trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0021","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","article-title":"The impact of response on bone-directed therapy in patients with multiple myeloma","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0022","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0023","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.028_bib0024","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.028_bib0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.07.028_bib0026","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0027","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.blo.0000131642.96984.74","article-title":"Kyphoplasty enhances function and structural alignment in multiple myeloma","volume":"426","author":"Lane","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.clml.2021.07.028_bib0029","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.joms.2015.09.024","article-title":"Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw","volume":"73","author":"Ruggiero","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clml.2021.07.028_bib0030","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics","volume":"70","author":"Freiberger","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clml.2021.07.028_bib0031","first-page":"572","article-title":"Artifactual hypercalcemia in multiple myeloma","volume":"57","author":"Annesley","year":"1982","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.028_bib0032","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0033","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0034","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/bmj.288.6428.1411","article-title":"Analysis and management of renal failure in fourth MRC myelomatosis trial","volume":"288","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.clml.2021.07.028_bib0035","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.07.028_bib0036","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0037","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0038","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1542-4758.2010.00481.x","article-title":"Role of plasmapheresis in the management of myeloma kidney: a systematic review","volume":"14","author":"Gupta","year":"2010","journal-title":"Hemodial Int"},{"key":"10.1016\/j.clml.2021.07.028_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0041","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0042","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1538-7836.2006.02059.x","article-title":"Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide","volume":"4","author":"Palumbo","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.028_bib0043","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.028_bib0044","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/archinte.164.20.2260","article-title":"Venous thromboembolism according to age: the impact of an aging population","volume":"164","author":"Stein","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2021.07.028_bib0046","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1160\/TH13-02-0140","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.028_bib0047","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0048","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0049","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fonc.2019.00045","article-title":"Apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory therapy","volume":"9","author":"Cornell","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0051","unstructured":"Louzada M.L. ClinicalTrials.gov. Bethesda (MD): national library of medicine (US). Identifier NCT03428373, ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy. (RithMM). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03428373 (accessed January 27, 2020)."},{"key":"10.1016\/j.clml.2021.07.028_bib0052","unstructured":"Thrombosis Canada clinical guide committee. Thrombosis Canada clinical Guides. Whitby, ON: Thrombosis Canada; 2020. Available at: www.thrombosiscanada.ca\/clinicalguides. Accessed April 28, 2020."},{"key":"10.1016\/j.clml.2021.07.028_bib0053","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: chest guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.clml.2021.07.028_bib0054","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0055","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.028_bib0056","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0057","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1538-7836.2007.02613.x","article-title":"A pilot study of central venous catheter survival in cancer patients using low- molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)","volume":"5","author":"Kovacs","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.028_bib0058","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.12474","article-title":"Catheter-related thrombosis in cancer patients","volume":"162","author":"Murray","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0059","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3747\/co.22.2586","article-title":"Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis","volume":"22","author":"Easaw","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.028_bib0061","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/leu.2015.33","article-title":"Early mortality in multiple myeloma","volume":"29","author":"Costa","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.028_bib0062","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0063","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0064","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.028_bib0065","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0066","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/cid\/ciw838","article-title":"Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.07.028_bib0067","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41408-017-0002-2","article-title":"Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan","volume":"7","author":"Tsukune","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.07.028_bib0068","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/cid\/ciw337","article-title":"Too often forgotten: passive transfer of antibodies","volume":"63","author":"Thibault","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.07.028_bib0069","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1399-3062.2011.00655.x","article-title":"Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population","volume":"13","author":"Rogers","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clml.2021.07.028_bib0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes Zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.028_bib0071","first-page":"1901","article-title":"Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital","volume":"23","author":"Teh","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.07.028_bib0072","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in mm: first results from international myeloma society dataset","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0073","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-020-0879-9","article-title":"Multiple Myeloma and COVID-19","volume":"34","author":"Dhakal","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.028_bib0074","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of covid-19 pandemic: a consensus paper from the european myeloma network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.028_bib0075","series-title":"Recommendations On the Use of COVID-19 Vaccines","year":"2021"},{"key":"10.1016\/j.clml.2021.07.028_bib0076","series-title":"Coronavirus Disease (COVID-19): Prevention and Risks","year":"2021"},{"key":"10.1016\/j.clml.2021.07.028_bib0077","series-title":"Immunization of Immunocompromised persons: Canadian Immunization Guide","year":"2020"},{"key":"10.1016\/j.clml.2021.07.028_bib0078","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How i vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0079","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0080","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.028_bib0081","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0082","author":"Worksheet For Immunization of Adult Hematopoietic Stem Cell Transplant Recipients","year":"2020"},{"key":"10.1016\/j.clml.2021.07.028_bib0083","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2017.12.795","article-title":"Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance","volume":"24","author":"Palazzo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.028_bib0084","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.07.028_bib0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.07.028_bib0086","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.028_bib0087","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis","volume":"120","author":"Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clml.2021.07.028_bib0088","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tmrv.2016.06.006","article-title":"Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy","volume":"31","author":"Windegger","year":"2017","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.clml.2021.07.028_bib0089","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-2003-44554","article-title":"Hyperviscosity syndrome in plasma cell dyscrasias","volume":"29","author":"Mehta","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2021.07.028_bib0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.clml.2021.07.028_bib0091","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2021.07.028_bib0092","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.2011.08569.x","volume":"153","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0093","doi-asserted-by":"crossref","first-page":"628","DOI":"10.6004\/jnccn.2012.0064","article-title":"Cancer- and chemotherapy-induced anemia","volume":"10","author":"Rodgers","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2021.07.028_bib0094","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony- stimulating factors in multiple myeloma: is current clinical practice adequate?","volume":"97","author":"Leleu","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.07.028_bib0096","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0097","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0098","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa1411321","article-title":"Treatment of relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0099","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/154405910508400105","article-title":"Zinc gluconate in the treatment of dysgeusia\u2013a randomized clinical trial","volume":"84","author":"Heckmann","year":"2005","journal-title":"J Dent Res"},{"key":"10.1016\/j.clml.2021.07.028_bib0101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12883-016-0532-4","article-title":"Paraproteinemic neuropathy: a practical review","volume":"16","author":"Rison","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clml.2021.07.028_bib0102","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3109\/10428194.2011.598253","article-title":"Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis","volume":"52","author":"Malhotra","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.028_bib0103","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10072-016-2542-9","article-title":"An observational study assessing peripheral neuropathy related to multiple myeloma","volume":"37","author":"Leone","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clml.2021.07.028_bib0104","first-page":"4338","article-title":"Peripheral neuropathy is an under-recognized feature of monoclonal gammopathy of undetermined significance: a population-based study of 18,668 mgus patients and their 97,641 matched controls","volume":"130","author":"R\u00f6gnvaldsson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0105","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/NEN.0b013e3181af2b9c","article-title":"An update on nerve biopsy","volume":"68","author":"Vallat","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.clml.2021.07.028_bib0106","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.028_bib0107","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2021.07.028_bib0108","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/jnnp.57.Suppl.46","article-title":"Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy","volume":"57(Suppl)","author":"Leger","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clml.2021.07.028_bib0109","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clml.2021.07.028_bib0110","first-page":"165","article-title":"Pathophysiology of drug-induced peripheral neuropathy in patients with multiple myeloma","volume":"69(2)","author":"Luczkowska","year":"2018","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.clml.2021.07.028_bib0111","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/bmt.2015.83","article-title":"Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.028_bib0112","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0113","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.07.028_bib0114","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2021.07.028_bib0115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2009.07728.x","article-title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma","volume":"146","author":"Chen","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0116","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open- label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0117","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0118","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.seminhematol.2012.04.001","article-title":"General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma","volume":"49","author":"Broyl","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0119","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0120","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0121","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","article-title":"Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high- dose therapy","volume":"99","author":"Mateos","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.028_bib0122","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0123","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.028_bib0124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0125","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0126","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.028_bib0127","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.028_bib0128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/era.10.5","article-title":"Pain management in multiple myeloma","volume":"10","author":"Niscola","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2021.07.028_bib0129","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3747\/co.26.4261","article-title":"A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy","volume":"26","author":"Li","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2021.07.028_bib0130","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.07.028_bib0131","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/bmjspcare-2019-002032","article-title":"Cannabinoids for adult cancer-related pain: systematic review and meta-analysis","volume":"10","author":"Boland","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.clml.2021.07.028_bib0132","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","article-title":"Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data","volume":"16","author":"Andreae","year":"2015","journal-title":"J Pain"},{"key":"10.1016\/j.clml.2021.07.028_bib0133","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40265-019-01132-x","article-title":"Cannabinoids: current and future options to treat chronic and chemotherapy-induced neuropathic pain","volume":"79","author":"Blanton","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2021.07.028_bib0134","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/OGX.0000000000000812","article-title":"Use of cannabinoids in cancer patients: a society of gynecologic oncology (SGO) clinical practice statement","volume":"75","author":"Whitcomb","year":"2020","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.clml.2021.07.028_bib0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2021.07.028_bib0136","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/NCC.0b013e3181f9904d","article-title":"Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma","volume":"34","author":"Coleman","year":"2011","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.clml.2021.07.028_bib0137","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s12185-018-2516-1","article-title":"Clinical significance of cancer-related fatigue in multiple myeloma patients","volume":"108","author":"Suzuki","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0138","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/10428194.2020.1719091","article-title":"Health-related Quality of Life Results From the IFM 2009 Trial: treatment With Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma","volume":"61(6)","author":"Roussel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.028_bib0139","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.028_bib0140","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-14-496","article-title":"Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life","volume":"14","author":"Osborne","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2021.07.028_bib0141","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/pon.3284","article-title":"Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?","volume":"22","author":"Lamers","year":"2013","journal-title":"Psychooncology"},{"key":"10.1016\/j.clml.2021.07.028_bib0142","first-page":"374","article-title":"Treat patient, not just the disease: holistic needs assessment for haematological cancer patients","volume":"12","author":"Islam","year":"2018","journal-title":"Oncol Rev"},{"key":"10.1016\/j.clml.2021.07.028_bib0143","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clml.2021.07.028_bib0144","series-title":"Clinical Practice Guidelines We Can Trust","year":"2011"},{"key":"10.1016\/j.clml.2021.07.028_bib0145","series-title":"Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis","year":"2013"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:23Z","timestamp":1761871103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2152265021003116"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.028","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}